New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 30, 2014
08:32 EDTBTXBioTime unit announces $14.3M strategic partnership award from CIRM
Asterias Biotherapeutics, a subsidiary of BioTime, announced that it has been awarded a $14.3M Strategic Partnership III grant entitled “A Phase 1/2a Dose Escalation Study of AST-OPC1 in Patients with Cervical Sensorimotor Complete Cervical Spinal Cord Injury” from the California Institute for Regenerative Medicine. The award provides funding for Asterias to reinitiate clinical development of AST-OPC1 in subjects with spinal cord injury and to expand clinical testing of escalating doses in the target population intended for future pivotal trials.
News For BTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 22, 2015
08:09 EDTBTXBioTime announces nonexclusive license agreement with BRICOH
Subscribe for More Information
April 20, 2015
12:01 EDTBTXOncoCyte announces initial data from ongoing clinical study of PanC-Dx
BioTime and its subsidiary OncoCyte Corporation announced initial data from a large, prospective clinical study that showed the potential of PanC-Dx, OncoCyte’s non-invasive diagnostic technology based on its proprietary set of cancer markers, as a non-invasive, blood-based diagnostic test to screen for multiple types of human cancers, including breast cancer. The early data showed the utility of the protein Collagen Type X in distinguishing patients with malignant breast lesions from those with negative findings. The controlled study, initiated at Scottsdale Medical Imaging Laboratories in Scottsdale, AZ, is ongoing and has nearly completed enrollment of over 600 patients. The goal of this study is to assess the performance of PanC-Dx in discriminating patients with malignant breast lesions from those with negative findings or benign findings. Early data showed that PanC-Dx™ identified a mean concentration of COL10A1 protein in sera of breast cancer patients that was 35% higher than the mean COL10A1 value in sera of normal individuals (n=32). No significant differences were noted when comparing breast cancer patients to patients with confirmed benign disease suggesting that additional biomarkers may be necessary to discriminate these two populations.
06:32 EDTBTXBioTime and its subsidiary announce positive results from PanC-Dx studies
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use